1. Home
  2. TDF vs CERS Comparison

TDF vs CERS Comparison

Compare TDF & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

N/A

Current Price

$11.28

Market Cap

301.0M

Sector

Finance

ML Signal

N/A

Logo Cerus Corporation

CERS

Cerus Corporation

N/A

Current Price

$1.79

Market Cap

276.0M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
TDF
CERS
Founded
1994
1991
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
301.0M
276.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
TDF
CERS
Price
$11.28
$1.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
99.1K
1.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.27
EPS
N/A
N/A
Revenue
N/A
$51,326,000.00
Revenue This Year
N/A
$20.00
Revenue Next Year
N/A
$9.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.68
52 Week Low
$8.13
$1.12
52 Week High
$12.20
$2.96

Technical Indicators

Market Signals
Indicator
TDF
CERS
Relative Strength Index (RSI) 43.42 32.71
Support Level $11.29 $1.27
Resistance Level $11.42 $2.26
Average True Range (ATR) 0.17 0.17
MACD -0.02 -0.08
Stochastic Oscillator 44.29 5.24

Price Performance

Historical Comparison
TDF
CERS

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: